Aesthetic-laser maker Cynosure (NASDAQ:CYNO) announced yesterday that it had completed the acquisition of rival laser specialist Palomar Medical Technologies for $146 million cash and 6 million shares for a total value of around $294 million.

The combined company will have an installed base of more than 20,000 aesthetic-laser systems worldwide, with a distribution network that spans more than 100 countries. The two laser makers had combined revenues of $234 million in 2012, with 52% of their product revenue coming from North America and 48% originating from international markets.

Cynosure Chairman and CEO Michael Davin said: "We believe the acquisition complements our product portfolio and customer base, provides new product and service revenues, strengthens our global distribution network, opens new cross-selling opportunities, and enhances our intellectual property position."

Under the terms of the agreement, each outstanding share of Palomar stock was converted into the right to receive $6.825 in cash and 0.2819 shares of Cynosure Class A common stock. The acquisition is expected to be accretive to Cynosure's earnings in  2014 with the synergies of $8 million to $10 million realized.  

Following the closing, Davin will continue to serve as Chairman and CEO; Palomar's Joseph Caruso joined Cynosure's board of directors as vice chairman, and he will serve as the combined company's president; and Timothy Baker will serve as executive VP, COO, and CFO.

Fool contributor Rich Duprey and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.